These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28186604)

  • 1. [Clinical and genetic features of a patient with myeloid neoplasm in association with PDGFRA and EVI1 gene rearrangements].
    Han W; Chao H; Zhou M; Cen L; Chen S; He X; Lu X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Feb; 34(1):93-97. PubMed ID: 28186604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
    Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
    Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
    De Weer A; Speleman F; Cauwelier B; Van Roy N; Yigit N; Verhasselt B; De Moerloose B; Benoit Y; Noens L; Selleslag D; Lippert E; Struski S; Bastard C; De Paepe A; Vandenberghe P; Hagemeijer A; Dastugue N; Poppe B;
    Haematologica; 2008 Dec; 93(12):1903-7. PubMed ID: 18815193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
    Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
    Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-related acute myeloid leukemia with eosinophilia, basophilia, t(4;14)(q12;q24) and PDGFRA rearrangement: a case report and review of the literature.
    Zhou J; Papenhausen P; Shao H
    Int J Clin Exp Pathol; 2015; 8(5):5812-20. PubMed ID: 26191303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations.
    Fink SR; Belongie KJ; Paternoster SF; Smoley SA; Pardanani AD; Tefferi A; Van Dyke DL; Ketterling RP
    Leuk Res; 2009 Jun; 33(6):843-6. PubMed ID: 19118897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.
    Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
    Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements.
    Madrigal I; Carrió A; Gómez C; Rozman M; Esteve J; Nomdedeu B; Campo E; Costa D
    Cancer Genet Cytogenet; 2006 Oct; 170(2):115-20. PubMed ID: 17011981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.
    Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
    Tang TC; Chang H; Chuang WY
    Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
    Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
    Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
    Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK
    Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia.
    Sugimoto Y; Sada A; Shimokariya Y; Monma F; Ohishi K; Masuya M; Nobori T; Matsui T; Katayama N
    Cancer Genet; 2015 Oct; 208(10):508-12. PubMed ID: 26319757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24).
    Lennon PA; Abruzzo LV; Medeiros LJ; Cromwell C; Zhang X; Yin CC; Kornblau SM; Konopieva M; Lin P
    Cancer Genet Cytogenet; 2007 Aug; 177(1):37-42. PubMed ID: 17693189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.
    Bobadilla D; Enriquez EL; Alvarez G; Gaytan P; Smith D; Slovak ML
    Br J Haematol; 2007 Mar; 136(6):806-13. PubMed ID: 17341266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
    Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
    Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.